The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics

SUZHOU, China, and ROCKVILLE, Md.: SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, Ph.D., Co-Founder and...

Click to view original post